<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Immune</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Genomics and Greywolf partner in autoimmune diseases</title>
      <description>
        <![CDATA[Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730795</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730795-genomics-and-greywolf-partner-in-autoimmune-diseases</link>
    </item>
    <item>
      <title>EQ-504 is AhR agonist for ulcerative colitis, related disorders</title>
      <description>
        <![CDATA[Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has recently presented data for their AhR agonist EQ-504 for the potential treatment of immune-related diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730794</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730794-eq-504-is-ahr-agonist-for-ulcerative-colitis-related-disorders</link>
    </item>
    <item>
      <title>New cGAS inhibitors reported in Riltide Medicines patent</title>
      <description>
        <![CDATA[Riltide Medicines Co. Ltd. has identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic disease, cardiovascular, dermatological, renal, respiratory, neurological and inflammatory disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730763</guid>
      <pubDate>Wed, 29 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730763-new-cgas-inhibitors-reported-in-riltide-medicines-patent</link>
    </item>
    <item>
      <title>Montai’s MTAI-1025 demonstrates efficacy in ulcerative colitis</title>
      <description>
        <![CDATA[The combination of impaired epithelial barrier function, mucosal inflammation and elevated oxidative stress is determinant for the pathogenesis of ulcerative colitis (UC). NF-E2-related factor 2 (NRF2) is an important transcription factor for modulating antioxidant defenses, inhibiting inflammatory pathways and regenerating the epithelial barrier. Montai Therapeutics Inc. has developed a potent and selective NRF2 agonist compound, MTAI-1025, for the management of UC using its proprietary CONECTA platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730743</guid>
      <pubDate>Wed, 29 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730743-montais-mtai-1025-demonstrates-efficacy-in-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>MFDS clears Curocell’s anbal-cel as first homegrown CAR T therapy </title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell Inc.’s <span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">Rimqarto&nbsp;</span>(anbalcabtagene-autoleucel; anbal-cel) April 29 as the first homegrown CAR T-cell therapy to treat patients with advanced diffuse large B-cell lymphomas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730685</guid>
      <pubDate>Wed, 29 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730685-mfds-clears-curocells-anbal-cel-as-first-homegrown-car-t-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Green-approved-stamp1.webp?t=1615578924" type="image/png" medium="image" fileSize="174851">
        <media:title type="plain">Green approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA proposes withdrawing Amgen’s Tavneos </title>
      <description>
        <![CDATA[Alleging “untrue statements” included in the approval application for vasculitis drug Tavneos (avacopan), the U.S. FDA’s Center for Drug Evaluation and Research is proposing to withdraw the NDA for small-molecule C5aR antagonist at the center of Amgen Inc.’s 2022 buyout of Chemocentryx Inc. for $3.7 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730788</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730788-fda-proposes-withdrawing-amgens-tavneos</link>
    </item>
    <item>
      <title>Pilatus PLT-012 takes immunometabolic approach to reprogram TME </title>
      <description>
        <![CDATA[Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors. “Traditional immunotherapies release immune ‘brakes,’ but they do not address the underlying metabolic stress in tumors,” Pilatus CEO and cofounder Raven Lin said. “That’s why more than 60% of solid tumor patients do not respond to treatment.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/730671</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730671-pilatus-plt-012-takes-immunometabolic-approach-to-reprogram-tme</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Monoclonal-antibody-cancer-tumor-illustration.webp?t=1765295036" type="image/jpeg" medium="image" fileSize="555950">
        <media:title type="plain">Illustration of monoclonal antibody treatment for cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>CARB-X award supports Adjane’s gonorrhea vaccine</title>
      <description>
        <![CDATA[CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is awarding US$2.6 million to Adjane Holding BV to advance the development of a vaccine candidate to prevent infections caused by <em>Neisseria gonorrhoeae</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730720</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730720-carb-x-award-supports-adjanes-gonorrhea-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Vaccine-research-vial-syringe.webp?t=1670859743" type="image/png" medium="image" fileSize="1080600">
        <media:title type="plain">Vaccine vial and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Totus presents first covalent small-molecule IRF5 inhibitors</title>
      <description>
        <![CDATA[The undrugged transcription factor interferon regulatory factor 5 (IRF5) is involved in autoimmune disorders such as Sjogren’s disease and rheumatoid arthritis in which dysregulation of IRF5 leads to autoantibody formation and secretion of pro-inflammatory cytokines, with type I interferon exacerbating inflammation. Totus Medicines Inc. has presented preclinical data regarding a novel IRF5 inhibitor for controlling autoimmune disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730699</guid>
      <pubDate>Mon, 27 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730699-totus-presents-first-covalent-small-molecule-irf5-inhibitors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Immune-response-macrophage-cytokines.webp?t=1675697811" type="image/png" medium="image" fileSize="1378465">
        <media:title type="plain">Macrophage releasing cytokines as a part of the body's immune response.</media:title>
      </media:content>
    </item>
    <item>
      <title>Anaptysbio’s spinout First Tracks hits the slopes</title>
      <description>
        <![CDATA[Anaptysbio Inc. announced in September of 2025 that it planned to separate its drug development business from the royalties it receives on Jemperli (dostarlimab) from GSK plc and imsidolimab from Vanda Pharmaceuticals Inc. Just seven months later, on April 20, 2026, well ahead of its “year-end 2026” goal, First Tracks Biotherapeutics Inc., the drug development arm of the company, started trading as a standalone company on Nasdaq under the ticker symbol TRAX.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730618</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730618-anaptysbios-spinout-first-tracks-hits-the-slopes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-structures-microscope.webp?t=1682529172" type="image/png" medium="image" fileSize="579163">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>CHMP gives nod for Sanofi’s Cenrifki for multiple sclerosis</title>
      <description>
        <![CDATA[Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion recommending approval in the EU.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730614</guid>
      <pubDate>Fri, 24 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730614-chmp-gives-nod-for-sanofis-cenrifki-for-multiple-sclerosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Stamp-with-EU-flag.webp?t=1724705102" type="image/jpeg" medium="image" fileSize="184762">
        <media:title type="plain">Stamp with EU flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Walking the talk, Kyverna phase II stiffens miv-cel CAR T case</title>
      <description>
        <![CDATA[Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational trial, KYSA-8, of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome. Kyverna plans to submit a BLA to the U.S. FDA in the first half of this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730495</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730495-walking-the-talk-kyverna-phase-ii-stiffens-miv-cel-car-t-case</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Woman-stretching-her-arms-and-hands.webp?t=1776888974" type="image/jpeg" medium="image" fileSize="445659">
        <media:title type="plain">Woman stretching her arms and hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Elpiscience’s bispecific antibody ES-302 reduces disease activity in IBD model</title>
      <description>
        <![CDATA[Researchers from Elpiscience Biopharmaceuticals Inc. hypothesized that dual targeting of the TL1A/DR3 and IL-23 signaling pathways with a single bispecific antibody would exert superior efficacy by reshaping the immune landscape in disorders such as inflammatory bowel disease (IBD). The company has developed a bispecific antibody targeting both TL1A/DR3 and IL-23p19 – ES-302 – for the treatment of IBD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730557</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730557-elpisciences-bispecific-antibody-es-302-reduces-disease-activity-in-ibd-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-vector-framework.webp?t=1739806991" type="image/jpeg" medium="image" fileSize="232822">
        <media:title type="plain">Illustration of intestinal track</media:title>
      </media:content>
    </item>
    <item>
      <title>Remedy pushes ‘cell-free’ secretome therapy for IPF into phase I </title>
      <description>
        <![CDATA[“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told <em>BioWorld</em>. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730576</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730576-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ayele-Dilion-Mashiah-CEO-Remedy-4-15.webp?t=1776282566" type="image/jpeg" medium="image" fileSize="469661">
        <media:title type="plain">Ayele Dilion Mashiah, CEO, Remedy</media:title>
        <media:description type="plain">Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Remedy pushes ‘cell-free’ secretome therapy for IPF into phase I </title>
      <description>
        <![CDATA[“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told <em>BioWorld</em>. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730310</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730310-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ayele-Dilion-Mashiah-CEO-Remedy-4-15.webp?t=1776282566" type="image/jpeg" medium="image" fileSize="469661">
        <media:title type="plain">Ayele Dilion Mashiah, CEO, Remedy</media:title>
        <media:description type="plain">Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Trained Therapeutix Discovery patents new mTOR inhibitors</title>
      <description>
        <![CDATA[Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially useful for the treatment of autoimmune diseases, transplant rejection, inflammatory and cardiovascular disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730385</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730385-trained-therapeutix-discovery-patents-new-mtor-inhibitors</link>
    </item>
    <item>
      <title>KDTV-001: a trivalent HPV vaccine with broad and durable antitumor immunity</title>
      <description>
        <![CDATA[While most human papillomavirus (HPV) infections are cleared by the host immune system, persistent infection with high-risk HPV genotypes, particularly HPV16 and HPV18, can promote cervical cancer development. Researchers from Huazhong University of Science and Technology reported the development and preclinical characterization of KDTV-001, an HPV vaccine comprising a nonreplicating adenovirus type 5 vector encoding a codon-optimized fusion protein of the early antigens E6 and E7 derived from HPV genotypes 16, 18 and 52.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730372</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730372-kdtv-001-a-trivalent-hpv-vaccine-with-broad-and-durable-antitumor-immunity</link>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730418</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730418-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Biohaven’s BHV-1450 shows promise for pemphigus vulgaris</title>
      <description>
        <![CDATA[Pemphigus vulgaris (PV) is a life-threatening autoimmune disease affecting the skin, causing painful erosions on the skin and mucous membranes. PV is caused by IgG4 autoantibodies that target desmoglein 1 (DSG1) and DSG3, which are involved in keratinocyte cell-cell adhesion. There is a high unmet medical need for PV, since current therapies rely on systemic corticosteroids and immunosuppressants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730331</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730331-biohavens-bhv-1450-shows-promise-for-pemphigus-vulgaris</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline. At the start of the biotech industry, progress was slow. Between 1983 and 1995, the U.S. FDA approved an average of two biologics each year. Now, biologics have taken the lead by the smallest of margins, accounting for 50.1% of drugs in development at the start of 2026, according to the <em>Pharma Annual Review 2026</em>, published by Pharmaprojects, a firm that tracks global pharma R&D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730343</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730343-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent presents data on IBI-3055 for autoimmune diseases</title>
      <description>
        <![CDATA[Innovent Biologics Inc. has presented preclinical data on IBI-3055, a trispecific T-cell engager for the treatment of autoimmune diseases. This trispecific antibody targets CD19, BCMA and CD3, and features an innovative 1+1+1 T-cell engager design with CD3 masking to minimize non-specific T-cell activation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730263</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730263-innovent-presents-data-on-ibi-3055-for-autoimmune-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/T-cells.webp?t=1579209494" type="image/png" medium="image" fileSize="414910">
        <media:title type="plain">T cells</media:title>
      </media:content>
    </item>
    <item>
      <title>TIPE2 silencing attenuates colitis</title>
      <description>
        <![CDATA[The tumor necrosis factor (TNF)-α-induced protein 8-like 2 (TIPE2), predominantly expressed in bone marrow-derived cells or lymphoid tissues, is an essential regulator of immune homeostasis. TIPE2 acts as a key negative modulator of inflammatory signaling through the suppression of toll-like receptor (TLR) activity, with TIPE2-deficient mice exhibiting spontaneous systemic inflammation and premature death.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730262</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730262-tipe2-silencing-attenuates-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-system-illustration.webp?t=1769098607" type="image/jpeg" medium="image" fileSize="679694">
        <media:title type="plain">Gastrointestinal system</media:title>
      </media:content>
    </item>
    <item>
      <title>Invivyd unveils measles monoclonal antibody candidate VMS-063</title>
      <description>
        <![CDATA[Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment and prevention of measles.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730261</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730261-invivyd-unveils-measles-monoclonal-antibody-candidate-vms-063</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Infection-measles-rash.webp?t=1775834424" type="image/jpeg" medium="image" fileSize="715450">
        <media:title type="plain">Photo of measles rash on skin</media:title>
      </media:content>
    </item>
    <item>
      <title>DXP-006 reduces disease severity in psoriasis models</title>
      <description>
        <![CDATA[Researchers from Singlomics Zhuhai Danxu Biopharmaceuticals Co. Ltd. presented DXP-006, a humanized antibody targeting IL1RAP, a shared co-receptor required for IL-1, IL-33 and IL-36 cytokines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730258</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730258-dxp-006-reduces-disease-severity-in-psoriasis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Dermatology-skin-layer-doctor.webp?t=1732551251" type="image/jpeg" medium="image" fileSize="478968">
        <media:title type="plain">Doctor holding illustration of cross section of skin</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730211</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730211-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Milestone under Cue and Boehringer Ingelheim collaboration</title>
      <description>
        <![CDATA[Cue Biopharma Inc. has reached a preclinical milestone in its collaboration and license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, following the latter’s selection of a first compound for lead optimization. The milestone triggers a $7.5 million payment to Cue.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730239</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730239-milestone-under-cue-and-boehringer-ingelheim-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Lymphocyte-tcell-bcell.webp?t=1726498696" type="image/jpeg" medium="image" fileSize="222409">
        <media:title type="plain">Illustration of lymphocytes</media:title>
      </media:content>
    </item>
    <item>
      <title>COVID-19 mRNA vaccine provides broad-spectrum protection</title>
      <description>
        <![CDATA[Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730096</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730096-covid-19-mrna-vaccine-provides-broad-spectrum-protection</link>
    </item>
    <item>
      <title>Hangzhou Innogate Pharma and Innorace Biopharma report new cGAS inhibitors</title>
      <description>
        <![CDATA[Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730066</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730066-hangzhou-innogate-pharma-and-innorace-biopharma-report-new-cgas-inhibitors</link>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
